Targeted Therapies for IgA Nephropathy: How Chinese Innovative Drugs Telitacicept and Iptacopan Are Leading Global Kidney Care

Author: DengYue International Business Division

At the end of 2023, Calliditas Therapeutics’ targeted-release budesonide (Nefecon®) officially entered the Chinese market through licensing and commercialization agreements, marking a pivotal milestone for IgA nephropathy (IgAN) management in China. Subsequently, several high-value therapeutic assets—including endothelin receptor antagonists and B-cell modulators—have entered regulatory submission or priority review pathways, signaling a critical transition: IgAN is evolving from a “passive management disease” to an “intervenable, potentially reversible chronic kidney disease” paradigm.

From a commercial perspective, these collaborations generally adopt regional licensing, milestone payments, and revenue-sharing structures, reflecting sustained confidence from multinational pharmaceutical companies and domestic innovators in China’s kidney disease market. With maturing regulatory, scientific, and reimbursement frameworks, IgAN is now one of the few disease areas where translational research logic and commercial strategy are closely aligned.

Disease Burden and Precision Targeting in IgA Nephropathy

IgAN is the most prevalent primary glomerular disease worldwide, accounting for 40–50% of primary glomerulonephritis cases in China. Epidemiological studies indicate that approximately 35–50% of patients progress to end-stage renal disease (ESRD) within 20–25 years, ultimately requiring dialysis or kidney transplantation.

Historically, IgAN standard therapy has relied on supportive treatment, primarily renin–angiotensin system (RAS) blockade using ACE inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). While these therapies reduce proteinuria and improve hemodynamics, they do not target the underlying immunopathogenesis, leaving many patients at risk of irreversible disease progression.

The central question has shifted from whether innovation is needed to which pathogenic pathways should be specifically targeted to alter the natural history of disease.

Current mechanistic understanding supports a “multi-hit” model:

1.  Overproduction of galactose-deficient IgA1 (Gd-IgA1)

2.  Formation of autoantibodies against Gd-IgA1

3.  Deposition of immune complexes in the glomerular mesangium

4.  Complement activation, glomerular inflammation, and fibrosis

This framework provides multiple therapeutic entry points: gut mucosal immunity, B-cell signaling (BAFF/APRIL), complement system modulation, and hemodynamic pathways mediated by endothelin or angiotensin.

Core IgAN Therapies: Mechanisms, Clinical Evidence, and Real-World Application

Innovative IgAN therapies now span several parallel targeted strategies with clear mechanistic rationale and clinical evidence. Key global IgAN therapies are summarized below:

This highlights multiple mechanistically distinct treatment paths: causal therapy, targeted anti-inflammatory approaches, progression risk control, and immunological source interventions. Each therapy has distinct targets, administration routes, and regulatory statuses.

DengYue will focus on the four therapies approved in China, analyzing their mechanisms, clinical evidence, real-world application, and safety profile to provide a comprehensive view of current and future IgAN management.

1. Nefecon® — Targeted-Release Budesonide

Mechanism: Modulates immune abnormalities in gut-associated lymphoid tissue (GALT)

China Status: Approved NMPA 24 Nov 2023; reimbursed 2025

US/EU Status: FDA/EMA full approval

Clinical Evidence:

1.  NefIgArd Phase III: 9-month treatment significantly reduces renal function decline; modeled ESRD onset delayed ~12.8 years; proteinuria significantly reduced

2.  Chinese subgroup: 24-month follow-up shows eGFR decline ~3.7 ml/min/1.73m²

3.  Post-treatment: risk reduction persists 15 months after cessation

Real-World Application:

● For adults with proteinuria and disease progression risk; combined with ACEI/ARB ± SGLT2 inhibitors

● Generally well tolerated; mild GI discomfort and headache; long-term steroid monitoring recommended

2. Iptacopan — First Oral Complement Factor B Inhibitor

Mechanism: Selectively inhibits alternative complement pathway to reduce complement-mediated glomerular inflammation; non-immunosuppressive precision therapy

China Status: Approved 2024.04; first domestic therapy targeting alternative complement pathway

US/EU Status: Approved for PNH; robust safety profile

Clinical Evidence:

1.  APPLAUSE-IgAN Phase III: reduces proteinuria, improves complement-driven biomarkers

2.  Especially effective in complement-activation-driven IgAN, supporting molecularly stratified therapy

Real-World Application:

● For patients with elevated complement markers or active inflammation; combination therapy with ACEI/ARB ± SGLT2 inhibitors

● Oral administration suitable for long-term chronic management; monitor infection risk and vaccination

3. Atrasentan — Selective ETA Receptor Antagonist

Mechanism: Inhibits endothelin A-mediated vasoconstriction, inflammation, and glomerulosclerosis; reduces proteinuria, slows renal progression

China Status: Conditional approval 2025.08 for high-risk IgAN

US/EU Status: Not approved

Clinical Evidence:

1.  AFFINITY study: 52-week treatment reduces 24-hour proteinuria ~45%; stable efficacy with RAS inhibitors

2.  Focused on glomerular hemodynamics and anti-fibrotic effects

Real-World Application:

● For persistent proteinuria patients needing additional risk reduction; combined with standard renal therapy

● Monitor edema, headache, liver function, fluid status

4. Telitacicept — BLyS/APRIL Dual-Target B-Cell Modulator

Mechanism: Recombinant fusion protein; inhibits BLyS and APRIL to suppress pathogenic B-cell and plasma cell activation; immune-source-targeted intervention

China Status: Approved 2021.03; initially for SLE and autoimmune disease

US/EU Status: Not approved for IgAN

Clinical Evidence:

1.  Phase II: 12-month high-dose therapy reduces proteinuria ~53%; slows renal function decline

2.  Targets disease at immunological origin

Real-World Application:

● Stronger immunosuppression than complement- or endothelin-targeted therapies; suitable for patients with significant immune abnormalities and persistent proteinuria

● Monitor infection risk, immunoglobulin levels, injection-site reactions; strict immune surveillance necessary

Global IgA Nephropathy Treatment Market Outlook and Multinational Pharma Expansion Strategies

Market Size and Growth Drivers

The global IgA nephropathy (IgAN) treatment market is projected to grow from approximately USD 1.56 billion in 2025 to nearly USD 5.89 billion by 2035, representing a compound annual growth rate (CAGR) of around 14.2%, indicating a period of rapid expansion over the next decade. In China, due to the high incidence and rapid progression of IgAN, the demand for innovative targeted therapies is particularly urgent. By 2033, the market size is expected to reach RMB 4.05–9.24 billion, making it one of the most strategically valuable single-country markets worldwide.

Multinational Pharma and Local Partnerships

Multinational companies such as Novartis and Travere leverage their mature global pipelines and extensive regulatory data to facilitate product launches in multiple regions. Local innovators and commercial partners, such as Yunding Xinyao, introduce leading global therapies into China through licensing and localized commercialization strategies, using their deep understanding of local clinical characteristics and regulatory policies to improve patient access and market coverage. This collaborative model provides clear synergies for accelerating global and local registrations, production scale-up, reimbursement negotiations, and real-world data collection.

Chronic Disease Drug Policies and Industry Trends

Regulatory Accelerated Pathways and Guideline Integration

China’s NMPA policies, including priority review and breakthrough therapy designation, have accelerated the approval of new therapies addressing high unmet needs in chronic diseases, with Nefecon® being a prime example. International guidelines, such as the latest KDIGO IgAN recommendations, have increasingly incorporated these innovative drugs, promoting a shift in clinical practice from “supportive management” toward “early intervention plus mechanism-based therapy.”

Real-World Evidence and Long-Term Efficacy Considerations

As Nefecon®, sparsentan, and atrasentan accumulate extensive real-world data globally and in China, clinical understanding of optimal treatment timing, combination therapy strategies, and long-term kidney function benefits has become clearer. This knowledge supports reimbursement strategy optimization and market maturation.

Combination Therapy and Targeted Treatment Trends

Future treatment models are expected to increasingly adopt combination strategies:

● Conventional blood pressure management plus SGLT2 inhibitors

● Targeting the immunologic root cause (e.g., Nefecon® or Iptacopan)

● Hemodynamic modulation (e.g., sparsentan or atrasentan)

● Personalized regimens guided by biomarkers

This trend aligns with the global paradigm of comprehensive kidney disease management and reflects the scientific rationale for multi-target intervention.

Conclusion

IgAN stands at a clear historical inflection point: transitioning from long-term reliance on supportive therapy as a “passive management disease” to a chronic kidney disease intervention stage guided by pathophysiology and precision targets.

With multiple innovative pathways advancing globally, IgAN is among the few nephrology fields with clear scientific rationale, demonstrable clinical benefit, and sustainable commercial potential. Efficiently linking innovative therapies with clinical needs, regulatory frameworks, and patient access is increasingly critical.

As a professional pharmaceutical import-export platform with sustained focus on global nephrology innovation, DengYueMed continues to provide insights from mechanistic interpretation, real-world evidence, and cross-regional market perspectives, helping stakeholders and patients fully understand the current and future landscape of IgAN treatment.